Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) EBIT (2016 - 2026)

Champions Oncology (CSBR) has 16 years of EBIT data on record, last reported at $185000.0 in Q4 2025.

  • For Q4 2025, EBIT fell 74.73% year-over-year to $185000.0; the TTM value through Oct 2025 reached $2.2 million, up 372.84%, while the annual FY2025 figure was $4.6 million, 161.9% up from the prior year.
  • EBIT reached $185000.0 in Q4 2025 per CSBR's latest filing, up from -$527000.0 in the prior quarter.
  • Across five years, EBIT topped out at $4.5 million in Q1 2025 and bottomed at -$2.6 million in Q1 2024.
  • Average EBIT over 5 years is -$372950.0, with a median of -$277500.0 recorded in 2022.
  • Peak YoY movement for EBIT: soared 3657.14% in 2021, then tumbled 28028.57% in 2023.
  • A 5-year view of EBIT shows it stood at $263000.0 in 2021, then tumbled by 97.34% to $7000.0 in 2022, then crashed by 28028.57% to -$2.0 million in 2023, then skyrocketed by 137.44% to $732000.0 in 2024, then crashed by 74.73% to $185000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were $185000.0 in Q4 2025, -$527000.0 in Q3 2025, and -$2.0 million in Q2 2025.